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Summary Oxaliplatin, the first available diaminocyclohexane platinum, has clinical activity in colorectal and ovarian cancers. Its mechanism
of action is thought to be similar to that of cisplatin, its main mechanism being the intrastrand DNA adduct between two adjacent guanins or
two adjacent guanine and adenine adducts. Ongoing molecular pharmacological studies of the mechanism of action of cisplatin suggest that
platinated adducts are recognized by proteins of the mismatch repair system, including the products of the hMLH1 and hMSH2 genes. DNA
mismatch repair defects occur in a wide variety of sporadic human cancers, are the main genetic factor in hereditary non-polyposis colon
cancer and a frequent de novo or acquired phenomenon in ovarian cancer and other solid tumours. Moreover, they have recently been
reported to be a cause of resistance to cisplatin but not to oxaliplatin, as diaminocyclohexane platinum adducts do not appear to be
recognized by the mismatch repair complex. These findings explain the oxaliplatin activity in some cisplatin-resistant tumours. In addition, the
good safety profile of oxaliplatin makes it a drug of choice for combination therapy, and it has been shown to be synergistic with other cytotoxic
agents, including 5-fluorouracil, cisplatin, carboplatin, topotecan, gemcitabine and CPT-11. The results of several ongoing trials are awaited,
but available data demonstrate that oxaliplatin is highly effective in the treatment of advanced colorectal and ovarian cancers. Promising early
results suggest that it is also efficacious in non-Hodgkin's lymphoma, breast and non-small-cell lung cancers. As a result of its mechanism of
action, its favourable safety profile and the differential profile of its antitumoral activity, the full potential of oxaliplatin as an active, versatile
antitumoral agent is yet to be fully explored.
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Oxaliplatin is a new diaminocyclohexane (DACH) platinum agent
that has non-cross-resistant characteristics with cisplatin and
carboplatin. It has been found to have a wide spectrum of activity
and has proved effective in colorectal cancer as first-line therapy
(Becouarn et al, 1997; Giacchetti et al, 1997) and in 5-fluorouracil
(5-FU)-refractory tumours (Andre et al, 1997; de Gramont et al,
1997), in advanced ovarian cancer as first-line treatment (Misset et
al, 1997) and also in pretreated cancers (Extra et al, 1990).
This new platinum derivative has an oxalate, which is the
hydrolysable ligand, and DACH, the non-leaving carrier ligand.
Like cisplatin, it acts as an alkylating agent on the DNA, forming
mainly platinated intrastrand links with two adjacent guanine or
two adjacent guanine and adenine adducts (Fink et al, 1997) (see
Figure 1). It is more potent than cisplatin, however, requiring
fewer DNA adducts to achieve an equal level ofcytotoxicity.
The difference between cisplatin and oxaliplatin is thought to be
the result of their varying effects on the mechanisms of resistance
rather than a fundamental difference in their modes of action.
Generally speaking, for all platinum compounds, there are six
ways in which a cell can become resistant to their effects (Gately
and Howell, 1993). There may be a decrease in the accumulation
ofthe drug, or an increased efflux, both ofwhich lead to a decrease
in intracellular concentrations of the compound. There may be
increased inactivation within the cell, or an increase in the
quenching of monoadducts. Finally, there could be an increase in
excision repair or an increase in post-replication repair/defect in
mismatch repair. These mechanisms are outlined in Figure 2. In
humans, there are at least five genes known to participate in the
mismatch repair process: hMLH1, hMSH2, hPMS1, hPMS2 and
GT-binding protein/p160. Defects in the repair system lead to a
general instability and an increase in DNA lesions. Germ-line
mutations in four of these genes lead to microsatellite instability.
Defects in hMLH1 and/or hMSH2 are known to cause 15-20% of
all cases of colorectal cancer. Furthermore, loss of the DNA
mismatch repair system occurs in a wide variety of sporadic
human cancers; it is a predisposing factor in hereditary non-
polyposis colorectal cancer, and is a frequent de novo or acquired
phenomenon in ovarian cancer (Brown et al, 1997).
Ongoing molecular pharmacological studies of the mechanism
of action of cisplatin and carboplatin suggest that platinated
adducts are recognized by proteins ofthe mismatch repair system,
including the products of the hMLHI and hMSH2 genes. Loss of
the mismatch repair system will therefore result in resistance to
cisplatin and carboplatin. Exposure to cisplatin has been proved to
select cellular populations with deficiencies in mismatch repair
(Fink et al, 1997).
In contrast to cisplatin, oxaliplatin adducts do not appear to be
well recognized by the repair protein complex. Consequently, loss
of this repair function does not affect the apoptotic response of the
cell to oxaliplatin. These observations imply that oxaliplatin is
selectively active in tumours exhibiting aberrancies of mismatch
repair, which are a cause ofresistance to the traditional platin agents.
Indeed, with the lack of cross-resistance between cisplatin and
oxaliplatin, cisplatin-resistant tumours may well respond to oxali-
platin. Oxaliplatin has been shown to be synergistic with other
compounds, including cisplatin, carboplatin, CPT-11, topotecan and
gemcitabine (Mathe et al, 1989; Alvarez et al, 1994; Ortuzar et al,
1994; Rixe et al, 1996; Brown et al, 1997; Raymond et al, 1997;
Zeghari-Squalli et al, 1997; S Faivre etal, personal communication).
OXALIPLATIN IN OVARIAN CANCER
In ovarian cancer (for which it has been reported that 20% of newly
diagnosed cases have a defect in the hMSH2 system), oxaliplatin has
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Figure 2 The possible resistance mechanisms of a cell to the platinum compounds
been shown to be as effective as a single agent in 4 of 15 patients who
were resistant to platinum compounds (Misset et al, 1991). A
compassionate-use phase II experience, initiated by Chollet et al
(1996), also showed that oxaliplatin, as monotherapy at a dose of
100-130 mg m-2 every 3 weeks, was effective in 9 of 34 evaluable
patients initially resistant or in relapse after treatment with
cisplatin/carboplatin therapy, giving an overall response rate of26%.
Partial responses were seen in 6 ofthe 13 platinum-sensitive patients
and in 3 ofthe 21 platinum-refractory patients.
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Oxaliplatin has also been used in combination with paclitaxel in
23 patients with recurrent ovarian cancer (Faivre et al, 1997).
Patients had received a median of two prior regimens. Oxaliplatin
was given at a dose of 100-130 mg m-2 and paclitaxel at a dose of
135-175 mg m-2 (i.v. for 3 h). Each therapy was given in an out-
patient setting, every 3 weeks for a median of six treatment cycles.
Of the 15 evaluable patients, three responded completely to treat-
ment, and six responded partially, giving an overall response rate of
60%. No major toxicity or treatment-related morbidity was seen.
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Table 1 The efficacy of oxaliplatin in combination with cisplatin, according
to platinum resistance status, in the treatment of ovarian cancer
Platinum Number of Response
resistance patients
status Complete Partial Total
Potentially sensitive 12 2 5 7
Primary refractory 2 0 0 0
Secondary refractory 11 0 3 3
Total 25 2 (8%) 8 (32%) 10 (40%)
From Chollet et al (1996).
In 25 patients with ovarian cancer, who had previously been
heavily treated with cisplatin/carboplatin, oxaliplatin at a dose of
130 mg m-2 was combined with cisplatin at a dose of 100 mg m-2,
each given every 3 weeks (Soulie et al, 1997). The results (shown
in Table 1) indicate an overall response rate of40%.
One EORTC ongoing phase II trial is comparing the effective-
ness ofoxaliplatin (130 mg m-2) with that oftaxol (175 mg m-2 i.v.
for 3 h) in patients with platinum-refractory advanced ovarian
cancer. Another multicentre phase II trial in France is investigating
the effectiveness of oxaliplatin (130 mg m-2) as monotherapy in
pretreated advanced ovarian cancer (Dieras et al, 1998). The
results ofboth studies should be available in 1998. Planned studies
include combinations of oxaliplatin with topotecan (phase I), with
taxol and cisplatin (phase II) and with taxol vs carboplatin and
taxol (phase 11111).
NEW COMBINATIONS IN GASTROINTESTINAL
CANCERS
A recent phase I trial has been carried out, in which oxaliplatin was
combined with CPT-11 in the treatment of advanced digestive
cancers (colorectal, gastric, pancreatic, hepatic, biliary tract,
oesophageal) (Cvitkovic et al, 1997). Oxaliplatin was given as
a 2-h i.v. infusion; 1 h after this had been completed, CPT-11
was given as a 30-min i.v. infusion. The treatment schedule
was repeated every 3 weeks, with escalating doses. A total of
26 patients were treated, including 17 patients with advanced
colorectal cancer, and there was a partial response in seven ofthese
mostly 5-FU refractory patients (giving a response rate of 40%).
Multicentre phase II and III studies are ongoing, with recom-
mended doses of 85 mg m-2 for oxaliplatin and 200 mg m-2 for
CPT-11 being administered to patients every 3 weeks. Other
planned studies include investigation of the safety and efficacy of
oxaliplatin in advanced pancreatic cancer, alone or in combination
with 5-FU. Oxaliplatin with CPT-11 or gemcitabine will also be
studied in this indication.
OTHER INDICATIONS
Oxaliplatin should also be considered for the treatment of other
neoplastic conditions. A phase 1/11 trial looked at oxaliplatin as
monotherapy in the treatment of heavily pretreated patients with
refractory/relapsed intermediate and low-grade non-Hodgkin's
lymphoma (Rotarski et al, 1993). Patients (n = 22) had previously
been treated with a median of two therapeutic regimens, and were
started on a dose of65 mg m-2 ofoxaliplatin. Treatment was given
every 3 weeks, and the dose was increased to 130 mg m-2. There
were nine responders, giving an overall response rate of41%. All
of the responders were patients with low-grade non-Hodgkin's
lymphoma (n = 15). The median response duration was 14 months
(range 3-40 months) and median progression-free survival was
12 months.
In metastatic breast cancer, there were three responses to oxali-
platin as a single agent in a phase I trial. In a pilot phase II study,
Garufi et al (1997) found that oxaliplatin, 130 mg m-2 adminis-
tered every 3 weeks, given to 14 anthracycline-resistant patients
with metastatic breast cancer resulted in a partial response in three
patients.
There is also an ongoing phase I/II trial evaluating the safety
and efficacy of oxaliplatin (130 mg m-2 on day 1) in combination
with navelbine (22-34 mg m-2 on days 1 and 8), given every
3 weeks to 45 patients with non-small-cell lung cancer (Monnet
et al, 1998). Full results are not yet available, but responses have
been seen at all dose levels tested so far, up to 32 mg m-2 navelbine
dose. Three further phase II trials are investigating the activity of
oxaliplatin alone and in combination with 5-FU in the treatment of
prostate, breast and gastric cancers.
CONCLUSIONS
The results of all of these trials are eagerly awaited, but it is clear
from data already available that oxaliplatin is a highly active agent
in the treatment ofcolorectal cancer and advanced ovarian cancer.
It is an ideal candidate for use in combination with many of the
well-established and new anti-cancer drugs, often resulting in
clinical synergy or additive effects. There are also promising early
results in the indications of non-Hodgkin's lymphoma, breast and
non-small-cell lung cancers. It is now in the hands of oncologists
to ensure that oxaliplatin is developed to achieve its full potential.
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